申请人:ratiopharm GmbH
公开号:EP3061461A1
公开(公告)日:2016-08-31
The present invention relates to mutants of Fibroblast Growth Factor (FGF), particularly FGF-20 and FGF-2 1, which contain newly introduced N-linked or O-linked glycosylation site(s). The polynucleotide coding sequences for the mutants, expression cassettes comprising the coding sequences, cells expressing the mutants, and methods for producing the mutants are also disclosed. Further disclosed are pharmaceutical compositions comprising the mutants and method for using the mutants.
本发明涉及成纤维细胞生长因子(FGF)的突变体,特别是含有新引入的N-连接或O-连接糖基化位点的FGF-20和FGF-2 1。还公开了突变体的多核苷酸编码序列、包含编码序列的表达盒、表达突变体的细胞以及生产突变体的方法。还公开了包含突变体的药物组合物和使用突变体的方法。